Clinical data

What are the features of an ideal pump insulin? 

Speed
NovoRapid^® has a rapid action that results in rapid delivery to the bloodstream with minimal delay between administration and pharmacological action.

Following information is published in: Heinemann L et al. Time-action profile of the insulin analoque B28Asp. Diabetic Medicine 1996; 13: 683-87.

NovoRapid^® has a rapid delivery to bloodstream

• Twice as fast absorption rate
• Twice as high peak concentration

NovoRapid^® has rapid action

• Faster onset of action: 10-20 vs. 30-60 minutes
• Shorter duration of action: 3-5 vs. 6-8 hours

Pump compatibility
NovoRapid^® remains physically stable with minimal crystalline aggregation or precipitation. Pump therapy with NovoRapid^® is associated with significantly less crystallisation compared with buffered human insulin. NovoRapid^® remains chemically stable in pump with no change in potency.

NovoRapid^® is highly compatible in pump use with low rates of crystallization

Following information is published in: Bode B et al. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001; 24:69-72. Read paper

• Pump occlusion due to insulin crystal formulation and precipitation in pump reservoir and distal tubing can result in clinically significant blood glucose fluctuations.
• Pump therapy with NovoRapid^® is associated with significantly less crystallization compared with buffered human insulin (p≤ 0.5)

NovoRapid^® is highly compatible in pump use with low risk of blockages

Following information is published in: Bode B et al. Comparison of insulin aspart to buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002; 25: 439-44. Read more

• The incidence of pump occlusion with NovoRapid^®   is low with approximately 80% of patients reporting 1 or less clogs or blockages per 4 weeks of use.
• It has been reported that patients utilizing an insulin pump and experiencing unpredictable glucose fluctuations should be advised to consider changing to NovoRapid^®. Read more 

Control
NovoRapid^® in pump therapy optimises long-term control in type 1 patients.

Following information is published in: Bode B et al. Comparison of insulin aspart to buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002; 25: 439-44. Read paper.

• NovoRapid^®  has ideal properties for use in pump therapy: soluble, rapid-acting, and uniform absorption characteristics
• In insulin pump therapy, NovoRapid^®   maintains good glycaemic control comparable with insulin lispro and buffered human insulin

• Pump therapy with NovoRapid^® significantly reduces post-dinner blood glucose (p = 0.019) compared with insulin lispro or buffered human insulin

NovoRapid^® reduces the incidence of hypoglycemic. Patients using NovoRapid^®   reported significantly fewer hypoglycaemic episodes than those using insulin lispro or buffered human insulin.

Following information is published in: Bode B et al. Comparison of insulin aspart to buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002; 25: 439-44. Read more

• Patients using NovoRapid^®  reported significantly fewer hypoglycaemic episodes than those using insulin lispro or buffered human insulin (p < 0.05 for both comparisons)
• Furthermore, there was a trend towards fewer hypoglycaemic episodes confirmed by blood glucose < 50 mg/dl in patients using NovoRapid^® between-group differences: ns)

NovoRapid^® lower the risk of nocturnal hypoglycaemia.

Following information is published in: Bode B et al. Comparison of insulin aspart to buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002; 25: 439-44. Read paper

• Patients on NovoRapid^® report significantly lower rates of nocturnal hypoglycaemic episodes than those using buffered human insulin (p = 0.004).
• Over a 12-week period, more patients using NovoRapid^®  were free of nocturnal hypoglycaemic episodes (41%) than patients on insulin lispro (25%) or buffered human insulin (20%)